Carcinoma, Non-Small-Cell Lung Clinical Trials

A listing of 48 Carcinoma, Non-Small-Cell Lung clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Carcinoma, Non-Small-Cell Lung

1 - 12 of 48

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 48 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.

Featured Trial

Non-Small Cell Lung Cancer Treatment

Recruiting

A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations

Conditions:

NSCLC

Lung Cancer

Non-Small Cell Lung Cancer

Carcinoma

Non-Small-Cell Lung

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

NCT05068024

Recruiting

The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.

Gender:

All

Ages:

18 years and above

Trial Updated:

07/20/2022

Locations: Gabrail Cancer Center, Canton, Ohio +1 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

NCT05298423

Recruiting

This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to cCRT followed by durvalumab with respect to the following... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/24/2024

Locations: VA Long Beach Healthcare System ( Site 2831), Long Beach, California +141 locations

VA Long Beach Healthcare System ( Site 2831), Long Beach, California

VA West Los Angeles Medical Center ( Site 2808), Los Angeles, California

Millennium Oncology Research Clinic ( Site 2801), Hollywood, Florida

Mid Florida Hematology and Oncology Center ( Site 2800), Orange City, Florida

University of Chicago Medical Center ( Site 2828), Chicago, Illinois

Franciscan St. Francis Health ( Site 2812), Indianapolis, Indiana

MFSMC-HJWCI ( Site 2804), Baltimore, Maryland

Boston Medical Center ( Site 2829), Boston, Massachusetts

University of Massachusetts Chan Medical School ( Site 2815), Worcester, Massachusetts

Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837), Springfield, Missouri

Rutgers Cancer Institute of New Jersey ( Site 2805), New Brunswick, New Jersey

Icahn School of Medicine at Mount Sinai ( Site 2821), New York, New York

White Plains Hospital ( Site 2835), White Plains, New York

Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816), Portland, Oregon

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827), Lancaster, Pennsylvania

Thomas Jefferson University - Clinical Research Institute ( Site 2813), Philadelphia, Pennsylvania

Millennium Research & Clinical Development ( Site 2811), Houston, Texas

Central Texas Veterans health care-Oncology & Hematology ( Site 2819), Temple, Texas

MultiCare Health System ( Site 2817), Tacoma, Washington

Canberra Hospital ( Site 0010), Canberra, Australian Capital Territory

Icon Cancer Centre Hobart ( Site 0003), Hobart, Tasmania

Ballarat Health Services-Medical Oncology ( Site 0002), Ballarat Central, Victoria

Frankston Hospital-Oncology and Haematology ( Site 0009), Frankston, Victoria

St Vincent's Hospital-Oncology Clinical Trials ( Site 0005), Melbourne, Victoria

Hospital Nossa Senhora da Conceição ( Site 0111), Porto Alegre, Rio Grande Do Sul

Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0105), Rio de Janeiro, Not set

A. C. Camargo Cancer Center-CAPEC ( Site 0102), Sao Paulo, Not set

James Lind Centro de Investigación del Cáncer ( Site 0202), Temuco, Araucania

Biocenter ( Site 0208), Concepción, Biobio

FALP-UIDO ( Site 0205), Santiago, Region M. De Santiago

Centro de Oncología de Precisión ( Site 0209), Santiago, Region M. De Santiago

Bradfordhill ( Site 0200), Santiago, Region M. De Santiago

ONCOCENTRO APYS-ACEREY ( Site 0203), Viña del Mar, Valparaiso

Beijing Cancer hospital-intrathoratic deparmtment II ( Site 0328), Beijing, Beijing

Beijing Cancer hospital-Oncology Radiotherapy Department ( Site 0309), Beijing, Beijing

Beijing Peking Union Medical College Hospital-pneumology department ( Site 0300), Beijing, Beijing

Army Medical Center of People's Liberation Army-Oncology Department ( Site 0321), Chongqing, Chongqing

Fujian Medical University Union Hospital-1 Bingfanglou ( Site 0330), Fuzhou Fujian, Fujian

Fujian Provincial Cancer Hospital ( Site 0316), Fuzhou, Fujian

The First Affiliated hospital of Xiamen University-oncology ( Site 0317), Xiamen, Fujian

Southern Medical University Nanfang Hospital-Department of Oncology ( Site 0336), Guangzhou, Guangdong

Fourth Hospital of Hebei Medical University ( Site 0331), Shijiazhuang, Hebei

Henan Cancer Hospital ( Site 0333), Zhengzhou, Henan

Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0315), Wuhan, Hubei

Hubei Cancer Hospital ( Site 0311), Wuhan, Hubei

Xiangya Hospital Central South University-Oncology department ( Site 0310), Changsha, Hunan

Hunan Cancer Hospital ( Site 0307), Changsha, Hunan

The Second Affiliated Hospital of Soochow University ( Site 0314), Suzhou, Jiangsu

Affiliated Hospital of Jiangsu University ( Site 0305), Zhenjiang, Jiangsu

Jilin Cancer Hospital-oncology department ( Site 0319), Changchun, Jilin

Shandong Provincial Hospital ( Site 0326), Jinan, Shandong

Qingdao Central Hospital-Endocrinology ( Site 0332), Qingdao, Shandong

Shanghai Chest Hospital-Radiotherapy Department ( Site 0306), Shanghai, Shanghai

Fudan University Shanghai Cancer Center ( Site 0304), Shanghai, Shanghai

Shanghai Pulmonary Hospital-Radiotherapy department ( Site 0335), Shanghai, Shanghai

Shanxi Cancer Hospital-Pulmonology ( Site 0322), Taiyuan, Shanxi

West China Hospital of Sichuan University ( Site 0324), Cheng Du, Sichuan

Tianjin Medical University Cancer Institute and Hospital-radiotherapy ( Site 0329), Tianjin, Tianjin

Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang

The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 0308), Hangzhou, Zhejiang

CIMCA ( Site 0501), San José, San Jose

PROCLINICAL Pharma ( Site 0504), San José, San Jose

Hospital Metropolitano - Sede Lindora ( Site 0503), Santa Ana, San Jose

Instituto de Oncologia ( Site 3003), Santo Domingo, Distrito Nacional

Onconet ( Site 3002), Distrito Nacional, Santo Domingo

Klinikum Chemnitz-Klinik für Innere Medizin IV ( Site 0607), Chemnitz, Sachsen

LungenClinic Grosshansdorf-Onkologie ( Site 0602), Grosshansdorf, Schleswig-Holstein

Universitaetsklinikum Schleswig-Holstein Campus Kiel-Medizinische Klinik II, Hämatologie und Onkolo, Kiel, Schleswig-Holstein

Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0603, Berlin, Not set

Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 0703), Athens, Attiki

Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0706), Athens, Attiki

Sotiria Thoracic Diseases Hospital of Athens ( Site 0704), Athens, Attiki

Metropolitan Hospital ( Site 0702), Athens, Attiki

General Oncology Hospital of Kifissia "Agioi Anargiroi"-2nd Department of Medical Oncology ( Site 07, Nea Kifissia, Attiki

University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0700), Heraklion, Irakleio

European Interbalkan Medical Center ( Site 0701), Thessaloniki, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 0802), Ciudad de Guatemala, Not set

Centro Regional de Sub Especialidades Médicas SA ( Site 0801), Quetzaltenango, Not set

Centro Medico Integral De Cancerología (CEMIC) ( Site 0805), Quetzaltenango, Not set

Rambam Health Care Campus-Oncology ( Site 1001), Haifa, Not set

Shaare Zedek Medical Center ( Site 1003), Jerusalem, Not set

Rabin Medical Center ( Site 1004), Petah Tikva, Not set

Sheba Medical Center-ONCOLOGY ( Site 1000), Ramat Gan, Not set

Sourasky Medical Center ( Site 1002), Tel Aviv, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia medica Toraco-Polmonare ( Site 1107), Napoli, Campania

Policlinico Universitario Campus Bio-Medico-Radiation Oncology ( Site 1101), Roma, Lazio

Ospedale San Raffaele ( Site 1104), Milano, Lombardia

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1100), Milan, Lombardia

Ospedale San Gerardo-ASST Monza-Oncologia ( Site 1102), Monza, Lombardia

Fondazione IRCCS Policlinico San Matteo ( Site 1103), Pavia, Lombardia

Azienda Ospedaliera Spedali Civili di Brescia ( Site 1105), Brescia, Not set

National Hospital Organization Shikoku Cancer Center ( Site 1211), Matsuyama, Ehime

Kurume University Hospital ( Site 1212), Kurume, Fukuoka

Kobe Minimally Invasive Cancer Center ( Site 1210), Kobe, Hyogo

Kanagawa cancer center ( Site 1204), Yokohama, Kanagawa

Miyagi Cancer Center ( Site 1200), Natori, Miyagi

Sendai Kousei Hospital ( Site 1213), Sendai, Miyagi

Niigata Cancer Center Hospital ( Site 1205), Niigata-shi, Niigata

Kansai Medical University Hospital ( Site 1207), Hirakata, Osaka

Osaka Medical and Pharmaceutical University Hospital ( Site 1208), Takatsuki, Osaka

Saitama Prefectural Cancer Center ( Site 1201), Ina-machi, Saitama

Japanese Foundation for Cancer Research ( Site 1202), Koto, Tokyo

Showa University Hospital ( Site 1203), Shinagawa, Tokyo

Osaka International Cancer Institute ( Site 1209), Osaka, Not set

Chungbuk National University Hospital-Internal medicine ( Site 2400), Cheongju-si, Chungbuk

The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2401), Suwon-si, Kyonggi-do

Ajou University Hospital-Hematology-Oncology ( Site 2402), Suwon-si, Kyonggi-do

Severance Hospital, Yonsei University Health System-Lung Cancer Center ( Site 2403), Seoul, Not set

University Malaya Medical Centre-Clinical Oncology ( Site 1402), Lembah Pantai, Kuala Lumpur

Hospital Pulau Pinang ( Site 1400), George Town, Pulau Pinang

Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1401), Kuala Lumpur, Not set

Arké SMO S.A. de C.V. ( Site 1504), Mexico, Distrito Federal

Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 1505), Guadalajara, Jalisco

Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 1507), Chihuahua, Not set

Centro de Investigacion Clinica de Oaxaca ( Site 1501), Oaxaca, Not set

Hospital CUF Descobertas ( Site 2006), Lisbon, Lisboa

Centro Hospitalar do Porto - Hospital de Santo António ( Site 2004), Porto, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2001), Porto, Not set

Centrul Medical Medicover Victoria ( Site 2106), Bucharest, Bucuresti

Amethyst Radiotherapy Center ( Site 2102), Florești, Cluj

Centrul de Oncologie "Sfântul Nectarie" ( Site 2100), Craiova, Dolj

Radiology Therapeutic Center ( Site 2108), Otopeni, Ilfov

Cabinet Medical Oncomed ( Site 2101), Timișoara, Timis

CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2304), Port Elizabeth, Eastern Cape

Wilgers Oncology Centre ( Site 2301), Pretoria, Gauteng

The Oncology Centre ( Site 2300), Durban, Kwazulu-Natal

Abraham Oncology ( Site 2303), Richards Bay, Kwazulu-Natal

Cape Town Oncology Trials ( Site 2306), Cape Town, Western Cape

HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit, Barcelona, Cataluna

CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2502), Santiago de Compostela, La Coruna

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2504), Pozuelo de Alarcon, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron ( Site 2501), Barcelona, Not set

Medipol Mega Universite Hastanesi-oncology ( Site 2611), Stanbul, Istanbul

Ege University Medicine of Faculty-Chest Diseases Department ( Site 2603), Bornova, Izmir

I.E.U. Medical Point Hastanesi-Oncology ( Site 2612), Izmir, Karsiyaka, Izmir

Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2607), Adana, Not set

Ankara Gülhane Eitim ve Aratrma Hastanesi-Oncology ( Site 2602), Ankara, Not set

Hacettepe Universitesi-oncology hospital ( Site 2605), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 2609), Ankara, Not set

Ankara City Hospital-Medical Oncology ( Site 2601), Ankara, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2610), Istanbul, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Recruiting

This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and three substudies. Each substudy will enroll a different population of NSCLC participants. The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 4 substudies. Participants mus... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +38 locations

Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona

City of Hope ( Site 0014), Duarte, California

UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California

Georgetown University ( Site 0036), Washington, District of Columbia

University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky

MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland

Massachusetts General Hospital ( Site 0003), Boston, Massachusetts

Dana Farber Cancer Institute ( Site 0002), Boston, Massachusetts

Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska

Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037), Hackensack, New Jersey

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034), New York, New York

Sanford Fargo Medical Center ( Site 0039), Fargo, North Dakota

Cleveland Clinic ( Site 0006), Cleveland, Ohio

Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus, Ohio

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania

Sanford Cancer Center ( Site 0038), Sioux Falls, South Dakota

The University of Texas MD Anderson Cancer Center ( Site 0009), Houston, Texas

Petz Aladar Megyei Oktato Korhaz ( Site 0062), Gyor, Gyor-Moson-Sopron

Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061), Szolnok, Jasz-Nagykun-Szolnok

Orszagos Koranyi Pulmonologiai Intezet ( Site 0060), Budapest, Not set

Soroka Medical Center ( Site 0072), Beer-Sheva, Not set

Rambam Health Care Campus-Oncology ( Site 0076), Haifa, Not set

Shaare Zedek Medical Center ( Site 0075), Jerusalem, Not set

Meir Medical Center ( Site 0071), Kfar-Saba, Not set

Rabin Medical Center ( Site 0074), Petah Tikva, Not set

Chaim Sheba Medical Center ( Site 0070), Ramat Gan, Not set

Sourasky Medical Center ( Site 0077), Tel Aviv, Not set

Azienda Ospedaliera Universitaria Careggi ( Site 0173), Florence, Firenze

Policlinico Gemelli di Roma ( Site 0174), Roma, Lazio

IRCCS Ospedale San Raffaele ( Site 0171), Milano, Not set

Seoul National University Bundang Hospital ( Site 0081), Seongnam-si, Kyonggi-do

Severance Hospital ( Site 0080), Seoul, Not set

Samsung Medical Center ( Site 0082), Seoul, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier, Warszawa, Mazowieckie

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdańsk, Pomorskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152), Koszalin, Zachodniopomorskie

ICO L Hospitalet ( Site 0090), Hospitalet de Llobregat, Barcelona

Hospital Universitario Quiron Madrid ( Site 0091), Pozuelo de Alarcon, Madrid

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

NCT05642195

Recruiting

Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back. Objective: To test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803)... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas

Learn More ›

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314

Recruiting

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD[s]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama +76 locations

University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama

The Oncology Institute of Hope and Innovation, Cerritos, California

UCLA, Los Angeles, California

Montefiore Einstein Center for Cancer Care, Bronx, New York

Virginia Cancer Specialists, Fairfax, Virginia

PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Not set

CIONC Centro Integrado de Oncologia de Curitiba, Curitiba, Not set

UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, Not set

Uniao Brasileira de Educaçao e Assistencia-Hospital Sao Lucas da PUCRS, Porto Alegre, Not set

Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, Not set

Instituto D Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Not set

Nucleo de Oncologia da Bahia, Salvador, Not set

Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Not set

Sociedade Beneficente de Senhoras - Hospital Sírio Libanês, São Paulo, Not set

The Ottawa Hospital Research Institute, Ottawa, Ontario

University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario

Sichuan Cancer Hospital, Chengdu, Not set

West China Hospital Sichuan University, Chengdu, Not set

Chongqing University Cancer Hospital, Chongqing, Not set

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Not set

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Not set

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Not set

Huizhou Municipal Central Hospital, Huizhou, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Shanghai Pulmonary Hospital, Shanghai, Not set

Shengjing Hospital of China Medical University, Shenyang, Not set

The First Affiliated Hospital of Xian Jiaotong University, Xi'An, Not set

Yantai Yuhuangding Hospital, Yantai, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Institute Coeur Poumon, Lille, Not set

CHU de la Timone, Marseille, Not set

Institut de cancerologie de l'ouest, Saint-Herblain Cedex, Not set

Nouvel Hopital Civil - CHU Strasbourg, Strasbourg cedex, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitaetsklinikum Koeln, Koeln, Not set

Universitaetsklinikum Muenster, Muenster, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Fondazione G Pascale Istituto Nazionale Tumori IRCCS, Napoli, Not set

Istituto Oncologico Veneto - IRCCS, Padova, Not set

Ospedale S. Maria Delle Croci, Ravenna, Not set

Istituto Nazionale Tumori Regina Elena, Rome, Not set

National Hospital Organization Nagoya Medical Center, Nagoya-shi, Not set

Shizuoka Cancer Center, Sunto-gun, Not set

The Cancer Institute Hospital of JFCR, Tokyo, Not set

Chungbuk National University Hospital, Cheongju-si, Not set

National Cancer Center, Goyang-Si, Not set

Gachon University Gil Hospital, Incheon, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

INSTYTUT GENETYKI I IMMUNOLOGII GENIM Sp z o o, Lublin, Not set

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, Not set

Hosp. Univ. A Coruna, A Coruna, Not set

Hosp. Gral. Univ. de Alicante, Alicante, Not set

Hosp. Del Mar, Barcelona, Not set

Hosp. Univ. Quiron Dexeus, Barcelona, Not set

Hosp. Univ. Vall D Hebron, Barcelona, Not set

Hosp. Clinic de Barcelona, Barcelona, Not set

Hosp. Univ. Fund. Jimenez Diaz, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. Univ. La Paz, Madrid, Not set

Hosp. Virgen Macarena, Sevilla, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

Gazi University Hospital, Ankara, Not set

Ankara Bilkent City Hospital, Ankara, Not set

Ankara Bilkent City Hospital, Cankaya, Not set

University College London Hospitals Nhs Foundation Trust, London, Not set

Imperial College London and Imperial College Healthcare NHS Trust, London, Not set

Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

NCT05908734

Recruiting

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: Virginia Cancer Specialists, Fairfax, Virginia +6 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786

Recruiting

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +8 locations

Conditions: Carcinoma, Non-small-Cell Lung

Learn More ›

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428

Recruiting

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: University of California at San Diego, La Jolla, California +108 locations

University of California at San Diego, La Jolla, California

University of California Irvine, Orange, California

Stanford Cancer Institute, Stanford, California

Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington, District of Columbia

Baptist Lynn Cancer Institute, Boca Raton, Florida

Mount Sinai Medical Center, Miami Beach, Florida

AdventHealth, Orlando, Florida

H. Lee Moffitt Cancer & Research Institute, Tampa, Florida

University of Kansas Cancer Center, Westwood, Kansas

Boston Medical Center, Boston, Massachusetts

Washington University School of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Hemotology Oncology Associates of CNY, East Syracuse, New York

Novant Health, Charlotte, North Carolina

Novant Health, Winston-Salem, North Carolina

Cleveland Clinic, Cleveland, Ohio

Cleveland Clinic, Mayfield Heights, Ohio

Cleveland Clinic, Warrensville Heights, Ohio

The Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Providence Regional Cancer Partnership, Everett, Washington

Virginia Mason Medical Center, Seattle, Washington

Swedish Cancer Institute, Seattle, Washington

Fundacao Pio XII, Barretos, Not set

PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Not set

Instituto do Cancer de Londrina - Hospital do Cancer de Londrina, Londrina, Not set

Associacao Hospitalar Moinhos de Vento, Porto Alegre, Not set

Instituto D Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Not set

Instituto D Or de Pesquisa e Ensino (IDOR), Salvador, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

Impar Servicos Hospitalares SA - Hospital Nove de Julho, Sao Paulo, Not set

Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Not set

Affiliated Hospital of Hebei University, Baoding, Not set

Jilin cancer hospital, Changchun, Not set

Sichuan Cancer Hospital, Chengdu, Not set

West China Hospital Sichuan University, Chengdu, Not set

The First Affiliated Hospital of PLA Army Medical University, ChongQing, Not set

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Not set

The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Not set

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Not set

Harbin medical university cancer hospital, Harbin, Not set

Huizhou Municipal Central Hospital, Huizhou, Not set

Liuzhou people's Hospital, Liuzhou, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Tianjin Medical University General Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Not set

Hospital of Jiangnan University, Wuxi, Not set

The First Affiliated Hospital of Xian Jiaotong University, XI An, Not set

Yantai Yuhuangding Hospital, Yantai, Not set

Centre Francois Baclesse, Caen Cedex 05, Not set

Centre Georges-François Leclerc, Dijon, Not set

Institut de Cancérologie du Gard, Nîmes, Not set

Institut Curie, PARIS Cedex 5, Not set

Institut de cancerologie de l'ouest, Saint-Herblain Cedex, Not set

Gustave Roussy, Villejuif Cedex, Not set

Evangelische Lungenklinik Berlin, Berlin, Not set

LungenClinic Grosshansdorf GmbH, Grosshandorf, Not set

Lungenfachklinik Immenhausen, Immenhausen, Not set

Universitaetsklinikum Koelnt, Koeln, Not set

Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Wuerzburg, Not set

Rambam Medical Center Department of Pediatric Pulmonology Meyer Childern's Hospital, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Meir Medical Center, Kfar Saba, Not set

Rabin Medical Center, Petah Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Policlinico Hospital San Martino- IRCCS for Oncology, Genova, Not set

Ospedale San Raffaele, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedaliera San Gerardo, Monza, Not set

Azienda Ospedaliera Specialistica dei Colli, Naples, Not set

National Hospital Organization Himeji Medical Center, Himeji, Not set

Matsusaka Municipal Hospital, Matsusaka, Not set

Niigata Cancer Center Hospital, Niigata, Not set

Shizuoka Cancer Center, Shizuoka, Not set

The Cancer Institute Hospital of JFCR, Tokyo, Not set

Wakayama Medical University Hospital, Wakayama, Not set

National Cancer Center, Goyang-Si, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Hospital Tengku Ampuan Afzan, Kuantan, Not set

Hospital Umum Sarawak, Kuching, Not set

Beacon Hospital Sdn Bhd, Petaling Jaya, Not set

Hosp. Univ. A Coruna, A Coruña, Not set

General University Hospital of Alicantet, Alacant, Not set

Hosp. Del Mar, Barcelona, Not set

Hosp. de La Santa Creu I Sant Pau, Barcelona, Not set

Hosp. Univ. Vall D Hebron, Barcelona, Not set

Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. Univ. La Paz, Madrid, Not set

Hosp. Regional Univ. de Malaga, Malaga, Not set

Hosp. Virgen Macarena, Sevilla, Not set

Hosp. Clinico Univ. de Valencia, Valencia, Not set

Hosp. Gral. Univ. Valencia, Valencia, Not set

Cheltenham General Hospital, Cheltenham, Not set

Torbay Hospital-Devon, Devon, Not set

Edinburgh Cancer Centre Western General, Edinburgh, Not set

Leicester Royal Infirmary, Leicester, Not set

University College London Hospitals, London, Not set

Nottingham City Hospital, Nottingham, Not set

Queen Alexandra Hospital, Portsmouth, Not set

Conditions: Carcinoma, Non-small-Cell Lung

Learn More ›

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140

Recruiting

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: City of Hope, Duarte, California +40 locations

City of Hope, Duarte, California

City of Hope Huntington Beach, Huntington Beach, California

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

City of Hope Long Beach Elm, Long Beach, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

Keck Hospital of USC, Los Angeles, California

USC Norris Oncology Hematology Newport Beach, Newport Beach, California

City of Hope South Pasadena, South Pasadena, California

Hope and Healing Care, Hinsdale, Illinois

Renown Regional Medical Center, Reno, Nevada

Hunterdon Hematology Oncology, Flemington, New Jersey

Clinical Research Alliance, Inc., Westbury, New York

Valley Medical Center, Renton, Washington

Gundersen Health System, W. Salem, Wisconsin

IADT Instituto Argentino de Diagnostico y Tratamiento, Caba, Not set

Changzhou No 2 Peoples Hospital, Changzhou, Not set

West China Hospital, Chengdou, Not set

Huizhou Municipal Central Hospital, Huizhou, Not set

Hopital Nord, Marseille Cedex 20, Not set

Hopital PASTEUR, Nice, Not set

Chungbuk National University Hospital, Cheongju-si, Not set

Gachon University Gil Hospital, Incheon, Not set

Hospital Pulau Pinang, Georgetown, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Hospital Tengku Ampuan Afzan, Kuantan, Not set

Hospital Umum Sarawak, Kuching, Not set

Hosp. Gral. Univ. de Alicante, Alicante, Not set

Hosp. Univ. Quiron Dexeus, Barcelona, Not set

Hosp. Univ. de Jaen, Jaen, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Ntra. Sra. de Valme, Sevilla, Not set

National Taiwan University Hospital Hsin-Chu Branch, Hsin Chu, Not set

Chang Kung Memorial Hospital, Kaohsiung City, Not set

Taichung Veterans General Hospital, Taichung City, Not set

National Taiwan University Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital, Taoyuan City, Not set

Adana City Hospital, Adana, Not set

Gulhane Training and Research Hospital, Ankara, Not set

Gazi University Hospital, Ankara, Not set

Ankara Bilkent City Hospital, Ankara, Not set

Ondokuz Mayis University, Samsun, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463

Recruiting

The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: USC - Norris Comprehensive Cancer Center, Los Angeles, California +77 locations

USC - Norris Comprehensive Cancer Center, Los Angeles, California

University of California Irvine, Orange, California

UCSF Helen Diller Comprehensive, San Francisco, California

Stanford University Medical Center, Stanford, California

Cedars Sinai Medical Center, West Hollywood, California

H. Lee Moffitt Cancer & Research Institute, Tampa, Florida

Massachusetts General Hospital, Boston, Massachusetts

Boston University Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Langone Health at NYC University, NYU School of Medicine, New York, New York

Columbia University Medical Center, New York, New York

Providence Portland Medical Center, Portland, Oregon

University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

University of Washington, Seattle, Washington

Beijing Cancer Hospital, Beijing, Not set

The First Bethune Hospital of Jilin University, Changchun, Not set

Hunan Cancer hospital, Changsha, Not set

West China School of Medicine/West China Hospital, Sichuan University, Chengdu, Not set

Chongqing University Cancer Hospital, Chongqing, Not set

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Not set

Zhejiang Cancer Hospital, Hang Zhou, Not set

Central Hospital of Jinan, Jinan, Not set

The Second Affiliated Hospital of Kunming Medical University, Kunming, Not set

Shanghai Chest Hospital, Shanghai, Not set

Shengjing Hospital of China Medical University, Shenyang, Not set

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Not set

Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Not set

The First Affiliated Hospital of Xian Jiaotong University, Xian, Not set

Institut Bergonié, Bordeaux, Not set

Centre Leon Berard, Lyon Cedex 8, Not set

CHU de la Timone, Marseille, Not set

Institut Curie, Paris, Not set

CHU De Poitiers, Poitiers, Not set

HIA Begin, Saint Mande, Not set

Institut Gustave Roussy, Villejuif Cedex, Not set

Evangelische Lungenklinik Berlin, Berlin, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Not set

Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting, Gauting, Not set

Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle (Saale), Not set

Lungenklinik Hemer, Hemer, Not set

Uniklinik Köln, Köln, Not set

Kliniiken der Stadt Köln gGmbH, Krankenhaus Köln-Mehrheim, Köln, Not set

Pius-Hospital Oldenburg, Oldenburg, Not set

Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Stuttgart, Not set

IRCCS Ospedale San Raffaele, Milano, Not set

IRCCS Istituto Europeo di Oncologia, Milano, Not set

San Gerardo Hospital, Monza, Not set

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Not set

Ospedale S. Maria Delle Croci, Ravenna, Not set

National Cancer Center Hospital, Chuo Ku, Not set

Kansai Medical University Hospital, Hirakata, Not set

Kobe City Medical Center General Hospital, Hyogo, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Aichi Cancer Center Hospital, Nagoya-Shi, Not set

Okayama University Hospital, Okayama, Not set

Shizuoka Cancer Center, Shizuoka, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Oncologic Hospital, Puerto Rico Medical Center, Rio Piedras, Not set

Hosp. Univ. Quiron Dexeus, Barcelona, Not set

Hosp. Univ. Vall D Hebron, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. Fund. Jimenez Diaz, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. Univ. Hm Sanchinarro, Madrid, Not set

Hosp. Virgen Del Rocio, Seville, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Not set

Chung Shan Medical University Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei City, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362

Recruiting

This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Part B), Safety and tolerability (Part C), and characterizati... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/22/2024

Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +28 locations

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

Ocala Oncology Center, Ocala, Florida

Advent Health, Orlando, Florida

Horizon Oncology Research, Lafayette, Indiana

Norton Cancer Institute, Downtown, Louisville, Kentucky

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Icahn School of Medicine at Mount Sinai, New York, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

Tennessee Oncology, PLLC, Nashville, Tennessee

Mary Crowley Cancer Research Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Cross Cancer Institute, Edmonton, Alberta

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario

Institut Bergonie, Bordeaux, Not set

Centre Leon Berard, Lyon, Not set

Institut Paoli-Calmettes, Marseille, Not set

Centre Eugene Marquis, Rennes, Not set

Institut Gustave Roussy, Villejuif, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI

Ospedale San Raffaele, Milan, Not set

Vall d'Hebron Institute of Oncology, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

START Madrid Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Next Oncology - Hospital Quironsalud Madrid, Pozuelo de Alarcon, Not set

Hospital Universitario Marques de Valdecilla, Santander, Not set

Sarah Cannon Research Institute UK, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasm

Learn More ›

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453

Recruiting

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: - Osimertinib (Tagrisso)

Gender:

All

Ages:

18 years and above

Trial Updated:

04/22/2024

Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

1 - 12 of 48